T-cell immunotherapy company Anocca AB reported on Wednesday the receipt of USD47m from its Series B financing led by Danske Bank, Swedbank Robur Ny Teknik, Ramsbury Invest.
This Series B financing was also led by significant family offices including Harald Mix, Robert Andreen, Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.
The funds will be used to further advance Anocca AB's industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. Its highly industrialised cellular biology platform replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders.
According to the company, its platform has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients